HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Imatinib mesylate can induce complete molecular remission in FIP1L1-PDGFR-a positive idiopathic hypereosinophilic syndrome.

AuthorsGiovanni Martinelli, Michele Malagola, Emanuela Ottaviani, Gianantonio Rosti, Elena Trabacchi, Michele Baccarani
JournalHaematologica (Haematologica) Vol. 89 Issue 2 Pg. 236-7 (Feb 2004) ISSN: 1592-8721 [Electronic] Italy
PMID15003901 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzamides
  • Enzyme Inhibitors
  • FIP1L1 protein, human
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • RNA, Messenger
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha
Topics
  • Aged
  • Benzamides
  • Enzyme Inhibitors (pharmacology, therapeutic use)
  • Exons (genetics)
  • HL-60 Cells
  • Humans
  • Hypereosinophilic Syndrome (drug therapy, genetics)
  • Imatinib Mesylate
  • Male
  • Oncogene Proteins, Fusion (antagonists & inhibitors, genetics)
  • Piperazines (pharmacology, therapeutic use)
  • Pyrimidines (pharmacology, therapeutic use)
  • RNA Splicing
  • RNA, Messenger (genetics)
  • Receptor, Platelet-Derived Growth Factor alpha (antagonists & inhibitors, genetics)
  • Remission Induction
  • mRNA Cleavage and Polyadenylation Factors (antagonists & inhibitors, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: